Study guide

6.2 Thyroid & Calcium Disorders

MRCPI in General Medicine Part I Written

Track your progress as you read

Finished sections get a check mark.

1 Chapter 1: Exam Structure, Strategy & Foundation

1.1 MRCPI Part I Format, Scoring & Standard-Setting 1.2 RCPI BST Curriculum & Single-Best-Answer Exam Strategy

2 Chapter 2: Cardiology & Vascular Medicine

2.1 Acute Coronary Syndromes & Stable Angina 2.2 Tachyarrhythmias, Bradyarrhythmias & Channelopathies 2.3 Heart Failure & Valvular Heart Disease 2.4 Hypertension, Vascular & Pericardial Diseases

3 Chapter 3: Respiratory Medicine

3.1 Asthma, COPD & Airway Diseases 3.2 Pneumonia, Tuberculosis & Respiratory Infections 3.3 Interstitial Lung Disease & Pleural Disorders 3.4 Pulmonary Embolism, Pulmonary Hypertension & Sleep Apnoea

4 Chapter 4: Gastroenterology & Hepatology

4.1 Upper & Lower GI Disorders & Inflammatory Bowel Disease 4.2 Acute & Chronic Liver Disease 4.3 Pancreatitis, Biliary Tract & GI Bleeding 4.4 Malabsorption, GI Motility & Clinical Nutrition

5 Chapter 5: Nephrology & Acid-Base Disorders

5.1 Acute Kidney Injury & Glomerular Diseases 5.2 Chronic Kidney Disease & Renal Replacement Therapy 5.3 Electrolyte Imbalances & Acid-Base Disorders

6 Chapter 6: Endocrinology & Diabetes

6.1 Diabetes Mellitus & Metabolic Complications 6.2 Thyroid & Calcium Disorders 6.3 Adrenal, Pituitary & Endocrine Syndromes

7 Chapter 7: Rheumatology & Clinical Immunology

7.1 Inflammatory Arthritides 7.2 Systemic Autoimmune & Vasculitic Diseases 7.3 Metabolic Bone Disease & Clinical Immunology

8 Chapter 8: Haematology & Medical Oncology

8.1 Anaemias, Haemostasis & Thrombosis 8.2 Leukaemias, Lymphomas & Plasma Cell Disorders 8.3 Medical Oncology & Oncological Emergencies

9 Chapter 9: Neurology & Dermatology

9.1 Stroke & Cerebrovascular Diseases 9.2 Epilepsy, Headache & Movement Disorders 9.3 Neuromuscular & Peripheral Nerve Disorders 9.4 Cutaneous Manifestations of Systemic Disease

10 Chapter 10: Acute Medicine, Critical Care & Geriatrics

10.1 Acute Poisoning & Toxidromes 10.2 Sepsis, Shock & Resuscitation 10.3 Geriatric Syndromes, Frailty & Comprehensive Care

11 Chapter 11: Clinical Pharmacology & Therapeutics

11.1 Pharmacokinetics & Pharmacodynamics 11.2 High-Risk Drug Classes & Prescribing Safety 11.3 Adverse Drug Reactions & Drug Safety

12 Chapter 12: Basic Sciences, Biostatistics & Clinical Ethics

12.1 Applied Cardiovascular & Respiratory Physiology 12.2 Clinical Biochemistry, Molecular Genetics & Microbiology 12.3 Biostatistics, Evidence-Based Medicine & Ethics

6.2 Thyroid & Calcium Disorders

Key Takeaways Explain This Topic AI

In thyroid storm (Burch-Wartofsky score > 45), propylthiouracil (PTU) must be administered at least 1 hour before potassium iodide (Lugol's solution) to prevent iodine substrate organification into new thyroid hormones.

Acute severe hypercalcemia (> 3.5 mmol/L) requires aggressive volume expansion with 3–6 L of 0.9% NaCl over 24 hours prior to or alongside IV zoledronic acid (4 mg over 15 mins).

Familial Hypocalciuric Hypercalcemia (FHH) is differentiated from primary hyperparathyroidism by a urine calcium-to-creatinine clearance ratio (UCCCR) < 0.01 (< 1%), preventing unnecessary surgery.

Levothyroxine replacement is indicated in subclinical hypothyroidism when serum TSH is ≥ 10 mU/L, during pregnancy, or when TSH is 5–10 mU/L with positive anti-TPO antibodies or symptoms.

Last updated: July 2026

  • 6.2 Thyroid & Calcium Disorders
  • Diagnostic Interpretation of Thyroid Function Tests

Evaluating serum thyroid-stimulating hormone (TSH), free T4 (FT4), and free T3 (FT3) requires systematic evaluation of hypothalamic-pituitary-thyroid axis negative feedback loops. Standard reference ranges typically define normal TSH as 0.4–4.5 mU/L, free T4 as 10–22 pmol/L, and free T3 as 3.5–6.5 pmol/L.

Biochemical Diagnostic Matrix

  • Clinical Condition TSH Free T4 Free T3 Key Diagnostic / Management Features
  • Primary Hypothyroidism High Low Low/Normal Anti-TPO antibodies positive in > 90% (Hashimoto's)
  • Primary Hyperthyroidism Low (< 0.05) High High TSH-receptor antibodies (TRAb) confirm Graves' disease
  • Subclinical Hypothyroidism High (5–10) Normal Normal Treat if TSH ≥ 10 mU/L, pregnant, or anti-TPO positive
  • Subclinical Hyperthyroidism Low (< 0.1) Normal Normal Associated with atrial fibrillation and osteoporosis

Sick Euthyroid Syndrome Low/Normal Low/Normal Low Non-thyroidal illness in acute ICU illness; recheck post-recovery

  • Central Hypothyroidism Low/Normal Low Low Pituitary failure; evaluate full anterior pituitary panel
  • TSH-Secreting Adenoma High/Normal High High Pituitary MRI; elevated serum alpha-subunit
  • Thyrotoxicosis & Thyroid Storm
  • Etiologies of Thyrotoxicosis

Graves' Disease : Autoimmune hyperthyroidism driven by TSH-receptor stimulating antibodies (TRAb). Features include a diffuse smooth goitre with vascular bruit, exophthalmos, pretibial myxedema, and thyroid acropachy. Radionuclide technetium-99m scan shows diffuse, homogenous high uptake. Treatment: Carbimazole (or Propylthiouracil in 1st trimester pregnancy due to carbimazole aplasia cutis risk). Severe active Graves' orbitopathy is treated with pulse intravenous Methylprednisolone (500 mg weekly for 6 weeks, then 250 mg weekly for 6 weeks).

Subacute (De Quervain's) Thyroiditis : Post-viral granulomatous thyroiditis. Presents with a painful, exquisitely tender goitre, fever, elevated ESR (> 50 mm/hr), and low radionuclide uptake (< 1%). Follows a triphasic course (thyrotoxic -> hypothyroid -> recovery). Treated with high-dose NSAIDs or Prednisolone (20–40 mg daily).

Toxic Multinodular Goitre (TMNG) & Toxic Adenoma : Hyperfunctioning autonomous nodules in older adults. Radionuclide scan shows patchy or focal high uptake with background suppression.

Amiodarone-Induced Thyrotoxicosis (AIT) : Type 1 (hyper-vascular, underlying Graves/nodules; treat with thionamides) vs. Type 2 (destructive inflammatory thyroiditis; treat with oral prednisolone).

Emergency Management of Thyroid Storm

Thyroid storm is a hypermetabolic emergency quantified by a Burch-Wartofsky Point Scale > 45 . Features include hyperpyrexia (> 38.5°C), severe tachycardia/atrial fibrillation, delirium/psychosis, and jaundice.

Sequential Pharmacological Protocol :

Propylthiouracil (PTU) : 400–600 mg loading dose orally/via NG tube, then 200 mg every 4 hours. Blocks new thyroid hormone synthesis and peripheral T4-to-T3 conversion.

Lugol's Iodine or Potassium Iodide : Administered at least 1 hour AFTER PTU . Inhibits pre-formed thyroid hormone release (Wolff-Chaikoff effect). Crucial Exam Pearl : Giving iodine prior to PTU provides substrate for further hormone synthesis (Jod-Basedow effect), worsening crisis.

Propranolol : 60–80 mg orally every 4 hours (or 1–2 mg IV) to control sympathetic hyperactivity and block peripheral T4-to-T3 conversion.

IV Hydrocortisone : 100 mg IV 6-hourly to prevent relative adrenal exhaustion and reduce peripheral T4-to-T3 conversion.

Hypothyroidism & Myxedema Coma

Replacement Therapy : Levothyroxine (T4) starting dose ~1.6 mcg/kg/day in young adults. In elderly patients or those with ischemic heart disease, start at 25–50 mcg/day to avoid precipitating angina. Monitor TSH at 6–8 weeks (target TSH 0.4–2.5 mU/L).

Myxedema Coma : Severe hypothyroidism presenting with hypothermia, hyponatremia, hypercapnia, and altered mental state. Management requires IV Levothyroxine (200–400 mcg loading) PLUS IV Hydrocortisone (100 mg stat) to prevent precipitating adrenal crisis in unrecognized concomitant hypopituitarism.

  • Disorders of Calcium & Parathyroid Homeostasis
  • Corrected Calcium Calculation

Total serum calcium must be corrected for serum albumin concentration:

  • Corrected Ca²⁺ (mmol/L) = Measured Ca²⁺ + 0.02 × (40 - Serum Albumin [g/L])
  • Hypercalcemia Differential Diagnosis Matrix

Feature Primary Hyperparathyroidism (PHPT) Malignancy (PTHrP Secretion) Familial Hypocalciuric Hypercalcemia (FHH)

  • Corrected Calcium Mildly/Moderately Elevated Severely Elevated (> 3.5 mmol/L) Mildly Elevated
  • Intact PTH High or Inappropriately Normal Suppressed (< 1.0 pmol/L) High or Inappropriately Normal
  • Serum Phosphate Low (< 0.8 mmol/L) Variable Normal/Low
  • Urine Ca:Cr Clearance Ratio > 0.02 (> 2%) High < 0.01 (< 1%)
  • Management Parathyroidectomy IV 0.9% NaCl + Zoledronic Acid Reassurance (Surgery Contraindicated)
  • Emergency Management of Acute Severe Hypercalcemia (> 3.5 mmol/L)

Isotonic Saline Hydration : Infuse 3–6 Liters of 0.9% NaCl over 24 hours to restore volume status and promote renal calcium clearance.

Intravenous Bisphosphonates : Administer Zoledronic Acid 4 mg IV over 15 minutes (or Pamidronate 60–90 mg). Full hypocalcemic onset requires 48–72 hours.

Calcitonin : 4–8 IU/kg SC/IM 12-hourly provides rapid calcium lowering within 2–4 hours (used as a bridge while awaiting bisphosphonate effect); limited by tachyphylaxis after 48 hours.

Hypocalcemia & Hypoparathyroidism

Etiologies : Surgical damage during thyroidectomy/parathyroidectomy (most common), autoimmune destruction, or magnesium depletion (hypomagnesemia inhibits PTH release and induces end-organ resistance).

Pseudohypoparathyroidism (Albright Hereditary Osteodystrophy) : End-organ PTH resistance due to GNAS gene mutations. Clinical signs include short stature, round facies, and short 4th/5th metacarpals. Biochemical panel demonstrates hypocalcemia, hyperphosphatemia, and elevated PTH .

Emergency Management of Acute Hypocalcemia : Symptomatic patients present with carpopedal spasm ( Trousseau's sign ), neuromuscular irritability ( Chvostek's sign ), or prolonged QTc interval. Administer 10 mL of 10% Calcium Gluconate IV over 10 minutes , followed by continuous IV infusion if required.